{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T23:25:48Z","timestamp":1794007548086,"version":"4.8.0"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,4,4]],"date-time":"2023-04-04T00:00:00Z","timestamp":1680566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,4,4]],"date-time":"2023-04-04T00:00:00Z","timestamp":1680566400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Patient Rep Outcomes"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>No available studies demonstrate validity and meaningful change thresholds of Work Productivity and Activity Impairment (WPAI) questionnaire in patients with migraine. In this post-hoc analysis, we assessed reliability, validity, responsiveness, and meaningful within-patient change from baseline to Month 3 for Work Productivity and Activity Impairment (WPAI) domain scores in patients with episodic migraine (EM) or chronic migraine (CM).<\/jats:p><\/jats:sec><jats:sec><jats:title>Method<\/jats:title><jats:p>The Phase 3, multicenter, randomized, double-blind, placebo-controlled CONQUER study (NCT03559257, N\u2009=\u2009462) enrolled patients with EM or CM who failed two to four categories of prior preventive medication in past ten years. The analyses were performed for WPAI domain scores (absenteeism, presenteeism, overall work productivity, and non-work-related activity impairment). Migraine Specific Quality of Life Questionnaire version 2.1 (MSQv2.1) domain scores (Role Function-Restrictive [RFR] and Role Function-Preventive [RFP]), and monthly migraine headache days were used as anchors. Responder criteria were changes from baseline to Month 3 for each of these anchors and were defined as: increase in MSQ-RFR by \u2265\u200925.71 points and MSQ-RFP by \u2265\u200920.00 points and a 50% reduction in monthly migraine headache days. Assessments were performed for overall population, and patients with EM or CM. The meaningful change threshold was determined based on Youden index, Phi coefficient and sensitivity.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Of 462 randomized patients, 444 who completed WPAI questionnaire were included in post-hoc analysis. Test\u2013retest reliability over 3\u00a0months in a stable subgroup revealed moderate correlations for non-work-related Activity Impairment (ICC\u2009=\u20090.446) presenteeism (ICC\u2009=\u20090.438) and a fair correlation for overall work productivity loss (ICC\u2009=\u20090.360). At baseline, all correlations between WPAI domain scores and continuous anchor variables exceeded recommended threshold of \u2265\u20090.30, except for WPAI domain scores with number of monthly migraine headache days. Patients achieving pre-specified responsiveness thresholds for monthly migraine headache days, and MSQ-RFP, MSQ-RFR from baseline to Month 3 (responders) showed significant improvements in WPAI domain scores compared with non-responders (<jats:italic>P<\/jats:italic>\u2009&lt;\u20090.001). The meaningful change thresholds of -20 (% unit) were identified for WPAI domain scores.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>In conclusion, WPAI has sufficient validity, reliability, responsiveness, and appropriate interpretation standards to assess the impact of EM or CM on presenteeism and overall work productivity loss and non-work-related activity impairment.<\/jats:p><\/jats:sec><jats:sec><jats:title><jats:italic>Trial registration<\/jats:italic><\/jats:title><jats:p>NCT number of CONQUER study, NCT03559257.<\/jats:p><\/jats:sec>","DOI":"10.1186\/s41687-023-00552-4","type":"journal-article","created":{"date-parts":[[2023,4,4]],"date-time":"2023-04-04T17:24:44Z","timestamp":1680629084000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Validation and meaningful within-patient change in work productivity and activity impairment questionnaire (WPAI) for episodic or chronic migraine"],"prefix":"10.1186","volume":"7","author":[{"given":"Janet H.","family":"Ford","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenyu","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David W.","family":"Ayer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaojuan","family":"Mi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Swati","family":"Bhandari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dawn C.","family":"Buse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard B.","family":"Lipton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,4,4]]},"reference":[{"issue":"9","key":"552_CR1","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1177\/0333102409355601","volume":"30","author":"TW Victor","year":"2010","unstructured":"Victor TW, Hu X, Campbell JC, Buse DC, Lipton RB (2010) Migraine prevalence by age and sex in the United States: a life-span study. Cephalalgia 30(9):1065\u20131072. https:\/\/doi.org\/10.1177\/0333102409355601","journal-title":"Cephalalgia"},{"issue":"1","key":"552_CR2","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/1129-2377-15-31","volume":"15","author":"TJ Steiner","year":"2014","unstructured":"Steiner TJ, Stovner LJ, Katsarava Z, Lainez JM, Lampl C, Lant\u00e9ri-Minet M, Rastenyte D, Ruiz de la Torre E, Tassorelli C, Barr\u00e9 J, Andr\u00e9e C (2014) The impact of headache in Europe: principal results of the Eurolight project. J Headache Pain 15(1):31. https:\/\/doi.org\/10.1186\/1129-2377-15-31","journal-title":"J Headache Pain"},{"key":"552_CR3","doi-asserted-by":"publisher","unstructured":"Diener HC, Ashina M, Durand-Zaleski I, Kurth T, Lant\u00e9ri-Minet M, Lipton RB, Ollendorf DA, Pozo-Rosich P, Tassorelli C, Terwindt G (2021) Health technology assessment for the acute and preventive treatment of migraine: a position statement of the International Headache Society. 41(3):279\u2013293. doi:https:\/\/doi.org\/10.1177\/0333102421989247","DOI":"10.1177\/0333102421989247"},{"key":"552_CR4","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/j.jns.2016.11.071","volume":"372","author":"YW Woldeamanuel","year":"2017","unstructured":"Woldeamanuel YW, Cowan RP (2017) Migraine affects 1 in 10 people worldwide featuring recent rise: a systematic review and meta-analysis of community-based studies involving 6 million participants. J Neurol Sci 372:307\u2013315. https:\/\/doi.org\/10.1016\/j.jns.2016.11.071","journal-title":"J Neurol Sci"},{"issue":"1","key":"552_CR5","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s10194-022-01402-2","volume":"23","author":"LJ Stovner","year":"2022","unstructured":"Stovner LJ, Hagen K, Linde M, Steiner TJ (2022) The global prevalence of headache: an update, with analysis of the influences of methodological factors on prevalence estimates. J Headache Pain 23(1):34. https:\/\/doi.org\/10.1186\/s10194-022-01402-2","journal-title":"J Headache Pain"},{"issue":"1","key":"552_CR6","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/s10194-019-0993-0","volume":"20","author":"M Leonardi","year":"2019","unstructured":"Leonardi M, Raggi A (2019) A narrative review on the burden of migraine: when the burden is the impact on people\u2019s life. J Headache Pain 20(1):41. https:\/\/doi.org\/10.1186\/s10194-019-0993-0","journal-title":"J Headache Pain"},{"issue":"7","key":"552_CR7","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1111\/head.13829","volume":"60","author":"SN Gibbs","year":"2020","unstructured":"Gibbs SN, Shah S, Deshpande CG, Bensink ME, Broder MS, Dumas PK, Buse DC, Vo P, Schwedt TJ (2020) United States patients\u2019 perspective of living with migraine: country-specific results from the global \u201cMy Migraine Voice\u201d survey. Headache 60(7):1351\u20131364. https:\/\/doi.org\/10.1111\/head.13829","journal-title":"Headache"},{"issue":"5","key":"552_CR8","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1177\/0333102418758283","volume":"38","author":"C Tassorelli","year":"2018","unstructured":"Tassorelli C, Diener HC, Dodick DW, Silberstein SD, Lipton RB, Ashina M, Becker WJ, Ferrari MD, Goadsby PJ, Pozo-Rosich P, Wang SJ (2018) Guidelines of the International Headache Society for controlled trials of preventive treatment of chronic migraine in adults. Cephalalgia 38(5):815\u2013832. https:\/\/doi.org\/10.1177\/0333102418758283","journal-title":"Cephalalgia"},{"issue":"10","key":"552_CR9","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1177\/0333102420941839","volume":"40","author":"HC Diener","year":"2020","unstructured":"Diener HC, Tassorelli C, Dodick DW, Silberstein SD, Lipton RB, Ashina M, Becker WJ, Ferrari MD, Goadsby PJ, Pozo-Rosich P, Wang SJ, Houle TT, Hoek T, Martinelli D, Terwindt GM (2020) Guidelines of the International Headache Society for controlled trials of preventive treatment of migraine attacks in episodic migraine in adults. Cephalalgia 40(10):1026\u20131044. https:\/\/doi.org\/10.1177\/0333102420941839","journal-title":"Cephalalgia"},{"key":"552_CR10","doi-asserted-by":"publisher","unstructured":"Yarlas A, Maher SM, Bayliss MS, Lovley A, Cappelleri JC, DiBonaventura MD (2018) Psychometric validation of the work productivity and activity impairment questionnaire in ulcerative colitis: results from a systematic literature review. J Patient Rep Outcomes 2(1):62. doi:https:\/\/doi.org\/10.1186\/s41687-018-0088-8","DOI":"10.1186\/s41687-018-0088-8"},{"key":"552_CR11","doi-asserted-by":"publisher","first-page":"647","DOI":"10.2147\/CEOR.S304158","volume":"13","author":"J Ford","year":"2021","unstructured":"Ford J, Nichols RM, Ye W, Tockhorn-Heidenreich A, Cotton S, Jackson J (2021) Patient-reported outcomes for migraine in the US and Europe: burden associated with multiple preventive treatment failures. Clinicoecon Outcomes Res 13:647\u2013660. https:\/\/doi.org\/10.2147\/CEOR.S304158","journal-title":"Clinicoecon Outcomes Res"},{"issue":"9","key":"552_CR12","doi-asserted-by":"publisher","first-page":"2003","DOI":"10.1111\/head.13946","volume":"60","author":"CR Houts","year":"2020","unstructured":"Houts CR, Wirth RJ, McGinley JS, Cady R, Lipton RB (2020) Determining thresholds for meaningful change for the Headache Impact Test (HIT-6) total and item-specific scores in chronic migraine. Headache 60(9):2003\u20132013. https:\/\/doi.org\/10.1111\/head.13946","journal-title":"Headache"},{"issue":"2","key":"552_CR13","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1111\/j.1524-4733.2006.00087.x","volume":"9","author":"DM Bushnell","year":"2006","unstructured":"Bushnell DM, Reilly MC, Galani C, Martin ML, Ricci JF, Patrick DL, McBurney CR (2006) Validation of electronic data capture of the Irritable Bowel Syndrome-Quality of Life Measure, the Work Productivity and Activity Impairment Questionnaire for Irritable Bowel Syndrome and the EuroQol. Value Health 9(2):98\u2013105. https:\/\/doi.org\/10.1111\/j.1524-4733.2006.00087.x","journal-title":"Value Health"},{"issue":"4","key":"552_CR14","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1111\/j.1365-2036.2004.02091.x","volume":"20","author":"MC Reilly","year":"2004","unstructured":"Reilly MC, Bracco A, Ricci JF, Santoro J, Stevens T (2004) The validity and accuracy of the Work Productivity and Activity Impairment questionnaire\u2013irritable bowel syndrome version (WPAI:IBS). Aliment Pharmacol Ther 20(4):459\u2013467. https:\/\/doi.org\/10.1111\/j.1365-2036.2004.02091.x","journal-title":"Aliment Pharmacol Ther"},{"issue":"2","key":"552_CR15","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1046\/j.1524-4733.2002.52101.x","volume":"5","author":"P Wahlqvist","year":"2002","unstructured":"Wahlqvist P, Carlsson J, St\u00e5lhammar NO, Wiklund I (2002) Validity of a work productivity and activity impairment questionnaire for patients with symptoms of gastro-esophageal reflux disease (WPAI-GERD)\u2013results from a cross-sectional study. Value Health 5(2):106\u2013113. https:\/\/doi.org\/10.1046\/j.1524-4733.2002.52101.x","journal-title":"Value Health"},{"issue":"2","key":"552_CR16","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1016\/j.clinthera.2008.02.016","volume":"30","author":"MC Reilly","year":"2008","unstructured":"Reilly MC, Gerlier L, Brabant Y, Brown M (2008) Validity, reliability, and responsiveness of the work productivity and activity impairment questionnaire in Crohn\u2019s disease. Clin Ther 30(2):393\u2013404. https:\/\/doi.org\/10.1016\/j.clinthera.2008.02.016","journal-title":"Clin Ther"},{"issue":"6","key":"552_CR17","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1016\/j.jval.2011.02.1179","volume":"14","author":"M Vergara","year":"2011","unstructured":"Vergara M, Montserrat A, Casellas F, Villoria A, Suarez D, Maudsley M, Gallardo O, Ricart E, Calvet X (2011) A new validation of the Spanish Work Productivity and Activity Impairment Questionnaire-Crohn\u2019s disease version. Value Health 14(6):859\u2013861. https:\/\/doi.org\/10.1016\/j.jval.2011.02.1179","journal-title":"Value Health"},{"issue":"2","key":"552_CR18","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1007\/s40271-014-0053-4","volume":"7","author":"J Lambert","year":"2014","unstructured":"Lambert J, Hansen BB, Arnould B, Grataloup G, Guillemin I, H\u00f8jbjerre L, Strandberg-Larsen M, Reilly MC (2014) Linguistic validation into 20 languages and content validity of the rheumatoid arthritis-specific Work Productivity and Activity Impairment questionnaire. Patient 7(2):171\u2013176. https:\/\/doi.org\/10.1007\/s40271-014-0053-4","journal-title":"Patient"},{"issue":"8","key":"552_CR19","doi-asserted-by":"publisher","first-page":"1364","DOI":"10.1093\/rheumatology\/kev435","volume":"55","author":"S Leggett","year":"2016","unstructured":"Leggett S, van der Zee-Neuen A, Boonen A, Beaton D, Bojinca M, Bosworth A, Dadoun S, Fautrel B, Hagel S, Hofstetter C, Lacaille D, Linton D, Mihai C, Petersson IF, Rogers P, Scir\u00e9 C, Verstappen SM (2016) Content validity of global measures for at-work productivity in patients with rheumatic diseases: an international qualitative study. Rheumatology (Oxford) 55(8):1364\u20131373. https:\/\/doi.org\/10.1093\/rheumatology\/kev435","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"552_CR20","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1186\/s10194-020-01144-z","volume":"21","author":"LP Wong","year":"2020","unstructured":"Wong LP, Alias H, Bhoo-Pathy N, Chung I, Chong YC, Kalra S, Shah ZUBS (2020) Impact of migraine on workplace productivity and monetary loss: a study of employees in banking sector in Malaysia. J Headache Pain 21(1):68. https:\/\/doi.org\/10.1186\/s10194-020-01144-z","journal-title":"J Headache Pain"},{"key":"552_CR21","doi-asserted-by":"publisher","first-page":"S61","DOI":"10.1016\/j.vhri.2019.08.342","volume":"19","author":"R Lenz Alcayaga","year":"2019","unstructured":"Lenz Alcayaga R, Paredes D, Hitschfeld M, Vo P, Quintana R, Carboni V (2019) PND12 work productivity and daily activities impairment (WPAI) in chilean patients with migraine: perspectives on indirect-costs drivers. Value Health Region Issues 19:S61. https:\/\/doi.org\/10.1016\/j.vhri.2019.08.342","journal-title":"Value Health Region Issues"},{"issue":"25","key":"552_CR22","doi-asserted-by":"publisher","first-page":"2397","DOI":"10.1056\/NEJMoa1312828","volume":"370","author":"KF Huybrechts","year":"2014","unstructured":"Huybrechts KF, Palmsten K, Avorn J, Cohen LS, Holmes LB, Franklin JM, Mogun H, Levin R, Kowal M, Setoguchi S, Hernandez-Diaz S (2014) Antidepressant use in pregnancy and the risk of cardiac defects. N Engl J Med 370(25):2397\u20132407. https:\/\/doi.org\/10.1056\/NEJMoa1312828","journal-title":"N Engl J Med"},{"issue":"7","key":"552_CR23","doi-asserted-by":"publisher","first-page":"e878","DOI":"10.1212\/wnl.0000000000010000","volume":"95","author":"RB Lipton","year":"2020","unstructured":"Lipton RB, Cohen JM, Gandhi SK, Yang R, Yeung PP, Buse DC (2020) Effect of fremanezumab on quality of life and productivity in patients with chronic migraine. Neurology 95(7):e878\u2013e888. https:\/\/doi.org\/10.1212\/wnl.0000000000010000","journal-title":"Neurology"},{"key":"552_CR24","doi-asserted-by":"publisher","unstructured":"Lipton RB, Lee L, Saikali NP, Bell J, Cohen JM (2020) Effect of headache-free days on disability, productivity, quality of life, and costs among individuals with migraine. 26(10):1344\u20131352. https:\/\/doi.org\/10.18553\/jmcp.2020.20103","DOI":"10.18553\/jmcp.2020.20103"},{"key":"552_CR25","doi-asserted-by":"publisher","first-page":"215013272095993","DOI":"10.1177\/2150132720959936","volume":"11","author":"AM Blumenfeld","year":"2020","unstructured":"Blumenfeld AM, Patel AT, Turner IM, Mullin KB, Manack Adams A, Rothrock JF (2020) Patient-reported outcomes from a 1-year, real-world, head-to-head comparison of onabotulinum toxin A and topiramate for headache prevention in adults with chronic migraine. J Prim Care Community Health 11:2150132720959936. https:\/\/doi.org\/10.1177\/2150132720959936","journal-title":"J Prim Care Community Health"},{"issue":"1","key":"552_CR26","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/s10194-021-01243-5","volume":"22","author":"T Shimizu","year":"2021","unstructured":"Shimizu T, Sakai F, Miyake H, Sone T, Sato M, Tanabe S, Azuma Y, Dodick DW (2021) Disability, quality of life, productivity impairment and employer costs of migraine in the workplace. J Headache Pain 22(1):29. https:\/\/doi.org\/10.1186\/s10194-021-01243-5","journal-title":"J Headache Pain"},{"key":"552_CR27","unstructured":"Lipton RB, Nelson AM, Nicholson RA, Zagar A, Kim Y, Pascual J, Evers S, Hirata K, Pearlman EM (2021) Migraine Diagnosis, Disability, and Work Productivity Impact in Migraine: Results of the OVERCOME (International) Study. Available via https:\/\/ihs-headache.org\/wp-content\/uploads\/2021\/11\/P0441_IHS2021_LIPTON__OVERCOME_INTL_BURDEN_MIGRAINE.pdf. Accessed 05 May 2022"},{"issue":"7","key":"552_CR28","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1111\/head.14151","volume":"61","author":"PM Estave","year":"2021","unstructured":"Estave PM, Beeghly S, Anderson R, Margol C, Shakir M, George G, Berger A, O\u2019Connell N, Burch R, Haas N, Powers SW, Seng E, Buse DC, Lipton RB, Wells RE (2021) Learning the full impact of migraine through patient voices: a qualitative study. Headache 61(7):1004\u20131020. https:\/\/doi.org\/10.1111\/head.14151","journal-title":"Headache"},{"issue":"10","key":"552_CR29","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1016\/s1474-4422(20)30279-9","volume":"19","author":"WM Mulleners","year":"2020","unstructured":"Mulleners WM, Kim BK, L\u00e1inez MJA, Lanteri-Minet M, Pozo-Rosich P, Wang S, Tockhorn-Heidenreich A, Aurora SK, Nichols RM, Yunes-Medina L, Detke HC (2020) Safety and efficacy of galcanezumab in patients for whom previous migraine preventive medication from two to four categories had failed (CONQUER): a multicentre, randomised, double-blind, placebo-controlled, phase 3b trial. Lancet Neurol 19(10):814\u2013825. https:\/\/doi.org\/10.1016\/s1474-4422(20)30279-9","journal-title":"Lancet Neurol"},{"key":"552_CR30","doi-asserted-by":"crossref","unstructured":"Garcia-Azorin D, Ford J, Buse D, Hand A, Wietecha L, Detke H (2020) Changes in work productivity and interictal burden: results from a randomized, double-blind, placebo-controlled clinical trial evaluating galcanezumab in adults with treatment-resistant migraine (CONQUER) (700). 94(15 Supplement):700","DOI":"10.1212\/WNL.94.15_supplement.700"},{"issue":"3","key":"552_CR31","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1016\/j.ogc.2018.04.007","volume":"45","author":"MC Kimmel","year":"2018","unstructured":"Kimmel MC, Cox E, Schiller C, Gettes E, Meltzer-Brody S (2018) Pharmacologic treatment of perinatal depression. Obstet Gynecol Clin North Am 45(3):419\u2013440. https:\/\/doi.org\/10.1016\/j.ogc.2018.04.007","journal-title":"Obstet Gynecol Clin North Am"},{"key":"552_CR32","unstructured":"IHS (2017) The International Classification of Headache Disorders 3rd Edition. Available via https:\/\/ichd-3.org\/1-migraine\/. Accessed 05 May 2022"},{"issue":"5","key":"552_CR33","doi-asserted-by":"publisher","first-page":"353","DOI":"10.2165\/00019053-199304050-00006","volume":"4","author":"MC Reilly","year":"1993","unstructured":"Reilly MC, Zbrozek AS, Dukes EM (1993) The validity and reproducibility of a work productivity and activity impairment instrument. Pharmacoeconomics 4(5):353\u2013365. https:\/\/doi.org\/10.2165\/00019053-199304050-00006","journal-title":"Pharmacoeconomics"},{"issue":"4","key":"552_CR34","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1046\/j.1526-4610.1998.3804295.x","volume":"38","author":"P Jhingran","year":"1998","unstructured":"Jhingran P, Osterhaus JT, Miller DW, Lee JT, Kirchdoerfer L (1998) Development and validation of the Migraine-Specific Quality of Life Questionnaire. Headache 38(4):295\u2013302. https:\/\/doi.org\/10.1046\/j.1526-4610.1998.3804295.x","journal-title":"Headache"},{"key":"552_CR35","doi-asserted-by":"publisher","unstructured":"Jhingran P, Davis SM, LaVange LM, Miller DW, Helms RW (1998) MSQ: migraine-specific quality-of-life questionnaire. further investigation of the factor structure. PharmacoEconomics 13(6):707\u2013717. https:\/\/doi.org\/10.2165\/00019053-199813060-00007","DOI":"10.2165\/00019053-199813060-00007"},{"issue":"3","key":"552_CR36","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1111\/head.14031","volume":"61","author":"RM Speck","year":"2021","unstructured":"Speck RM, Yu R, Ford JH, Ayer DW, Bhandari R, Wyrwich KW (2021) Psychometric validation and meaningful within-patient change of the Migraine-Specific Quality of Life questionnaire version 2.1 electronic patient-reported outcome in patients with episodic and chronic migraine. Headache 61(3):511\u2013526. https:\/\/doi.org\/10.1111\/head.14031","journal-title":"Headache"},{"issue":"5","key":"552_CR37","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1111\/j.1468-2982.2008.01555.x","volume":"28","author":"S Silberstein","year":"2008","unstructured":"Silberstein S, Tfelt-Hansen P, Dodick DW, Limmroth V, Lipton RB, Pascual J, Wang SJ (2008) Guidelines for controlled trials of prophylactic treatment of chronic migraine in adults. Cephalalgia 28(5):484\u2013495. https:\/\/doi.org\/10.1111\/j.1468-2982.2008.01555.x","journal-title":"Cephalalgia"},{"issue":"2","key":"552_CR38","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1111\/head.14069","volume":"61","author":"JS McGinley","year":"2021","unstructured":"McGinley JS, Houts CR, Nishida TK, Buse DC, Lipton RB, Goadsby PJ, Dodick DW, Wirth RJ (2021) Systematic review of outcomes and endpoints in preventive migraine clinical trials. Headache 61(2):253\u2013262. https:\/\/doi.org\/10.1111\/head.14069","journal-title":"Headache"},{"issue":"7","key":"552_CR39","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1007\/s11136-007-9217-1","volume":"16","author":"JC Cole","year":"2007","unstructured":"Cole JC, Lin P, Rupnow MF (2007) Validation of the Migraine-Specific Quality of Life Questionnaire version 2.1 (MSQ v. 2.1) for patients undergoing prophylactic migraine treatment. Qual Life Res 16(7):1231\u20131237. https:\/\/doi.org\/10.1007\/s11136-007-9217-1","journal-title":"Qual Life Res"},{"issue":"3","key":"552_CR40","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1111\/j.1526-4610.2011.01997.x","volume":"52","author":"CL Bagley","year":"2012","unstructured":"Bagley CL, Rendas-Baum R, Maglinte GA, Yang M, Varon SF, Lee J, Kosinski M (2012) Validating migraine-specific quality of life questionnaire v21 in episodic and chronic migraine. Headache 52(3):409\u2013421. https:\/\/doi.org\/10.1111\/j.1526-4610.2011.01997.x","journal-title":"Headache"},{"issue":"4 Suppl","key":"552_CR41","doi-asserted-by":"publisher","first-page":"142s","DOI":"10.1016\/s0197-2456(05)80019-4","volume":"12","author":"RA Deyo","year":"1991","unstructured":"Deyo RA, Diehr P, Patrick DL (1991) Reproducibility and responsiveness of health status measures: statistics and strategies for evaluation. Control Clin Trials 12(4 Suppl):142s-s158. https:\/\/doi.org\/10.1016\/s0197-2456(05)80019-4","journal-title":"Control Clin Trials"},{"issue":"1","key":"552_CR42","doi-asserted-by":"publisher","first-page":"159","DOI":"10.2307\/2529310","volume":"33","author":"JR Landis","year":"1977","unstructured":"Landis JR, Koch GG (1977) The measurement of observer agreement for categorical data. Biometrics 33(1):159\u2013174","journal-title":"Biometrics"},{"issue":"1","key":"552_CR43","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1097\/01.ede.0000147512.81966.ba","volume":"16","author":"EF Schisterman","year":"2005","unstructured":"Schisterman EF, Perkins NJ, Liu A, Bondell H (2005) Optimal cut-point and its corresponding Youden Index to discriminate individuals using pooled blood samples. Epidemiology 16(1):73\u201381. https:\/\/doi.org\/10.1097\/01.ede.0000147512.81966.ba","journal-title":"Epidemiology"},{"issue":"3","key":"552_CR44","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1111\/j.1365-2125.2005.02553.x","volume":"61","author":"ST Forgue","year":"2006","unstructured":"Forgue ST, Patterson BE, Bedding AW, Payne CD, Phillips DL, Wrishko RE, Mitchell MI (2006) Tadalafil pharmacokinetics in healthy subjects. Br J Clin Pharmacol 61(3):280\u2013288. https:\/\/doi.org\/10.1111\/j.1365-2125.2005.02553.x","journal-title":"Br J Clin Pharmacol"},{"issue":"2","key":"552_CR45","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/0304-3959(92)90154-4","volume":"50","author":"M Von Korff","year":"1992","unstructured":"Von Korff M, Ormel J, Keefe FJ, Dworkin SF (1992) Grading the severity of chronic pain. Pain 50(2):133\u2013149. https:\/\/doi.org\/10.1016\/0304-3959(92)90154-4","journal-title":"Pain"},{"issue":"1","key":"552_CR46","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/s0304-3959(00)00305-5","volume":"88","author":"WF Stewart","year":"2000","unstructured":"Stewart WF, Lipton RB, Kolodner KB, Sawyer J, Lee C, Liberman JN (2000) Validity of the migraine disability assessment (MIDAS) score in comparison to a diary-based measure in a population sample of migraine sufferers. Pain 88(1):41\u201352. https:\/\/doi.org\/10.1016\/s0304-3959(00)00305-5","journal-title":"Pain"},{"key":"552_CR47","doi-asserted-by":"publisher","unstructured":"Wu JJ, Lin C, Sun L, Goldblum O, Zbrozek A, Burge R, Augustin M, Feldman SR (2019) Minimal clinically important difference (MCID) for work productivity and activity impairment (WPAI) questionnaire in psoriasis patients. 33(2):318\u201324. https:\/\/doi.org\/10.1111\/jdv.15098","DOI":"10.1111\/jdv.15098"},{"key":"552_CR48","unstructured":"Qulipta (atogepant) Prescribing Information. Available on https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/215206Orig1s000lbl.pdf. Accessed on 17 Oct 2022"},{"key":"552_CR49","unstructured":"Emgality (galcanezumab) Prescribing Information. Available on https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/761063s004lbl.pdf. Accessed on 17 Oct 2022"},{"issue":"4","key":"552_CR50","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1093\/rheumatology\/kep457","volume":"49","author":"MC Reilly","year":"2010","unstructured":"Reilly MC, Gooch KL, Wong RL, Kupper H, van der Heijde D (2010) Validity, reliability and responsiveness of the Work Productivity and Activity Impairment Questionnaire in ankylosing spondylitis. Rheumatology 49(4):812\u2013819. https:\/\/doi.org\/10.1093\/rheumatology\/kep457","journal-title":"Rheumatology"},{"issue":"4","key":"552_CR51","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1177\/0333102419877171","volume":"40","author":"MA Chalmer","year":"2020","unstructured":"Chalmer MA, Hansen TF, Lebedeva ER, Dodick DW, Lipton RB, Olesen J (2020) Proposed new diagnostic criteria for chronic migraine. Cephalalgia 40(4):399\u2013406. https:\/\/doi.org\/10.1177\/0333102419877171","journal-title":"Cephalalgia"},{"issue":"2","key":"552_CR52","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1177\/0333102416636055","volume":"37","author":"M Torres-Ferr\u00fas","year":"2017","unstructured":"Torres-Ferr\u00fas M, Quintana M, Fernandez-Morales J, Alvarez-Sabin J, Pozo-Rosich P (2017) When does chronic migraine strike? A clinical comparison of migraine according to the headache days suffered per month. Cephalalgia 37(2):104\u2013113. https:\/\/doi.org\/10.1177\/0333102416636055","journal-title":"Cephalalgia"},{"issue":"7","key":"552_CR53","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1111\/head.14154","volume":"61","author":"R Ishii","year":"2021","unstructured":"Ishii R, Schwedt TJ, Dumkrieger G, Lalvani N, Craven A, Goadsby PJ, Lipton RB, Olesen J, Silberstein SD, Burish MJ, Dodick DW (2021) Chronic versus episodic migraine: the 15-day threshold does not adequately reflect substantial differences in disability across the full spectrum of headache frequency. Headache 61(7):992\u20131003. https:\/\/doi.org\/10.1111\/head.14154","journal-title":"Headache"},{"issue":"1","key":"552_CR54","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1177\/0333102419894559","volume":"40","author":"JL Brandes","year":"2020","unstructured":"Brandes JL, Diener HC, Dolezil D, Freeman MC, McAllister PJ, Winner P, Klatt J, Cheng S, Zhang F, Wen S, Ritter S, Lenz RA, Miko DD (2020) The spectrum of response to erenumab in patients with chronic migraine and subgroup analysis of patients achieving \u226550%, \u226575%, and 100% response. Cephalalgia 40(1):28\u201338. https:\/\/doi.org\/10.1177\/0333102419894559","journal-title":"Cephalalgia"}],"container-title":["Journal of Patient-Reported Outcomes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41687-023-00552-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s41687-023-00552-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41687-023-00552-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,10]],"date-time":"2023-12-10T06:08:06Z","timestamp":1702188486000},"score":1,"resource":{"primary":{"URL":"https:\/\/jpro.springeropen.com\/articles\/10.1186\/s41687-023-00552-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,4]]},"references-count":54,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["552"],"URL":"https:\/\/doi.org\/10.1186\/s41687-023-00552-4","relation":{},"ISSN":["2509-8020"],"issn-type":[{"value":"2509-8020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,4]]},"assertion":[{"value":"21 June 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 January 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 April 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study protocol was approved by the Institutional Review Board, Medical Ethics Committee or Medical Research, and Ethics Committee of the participating study sites. The study was conducted in concordance with the Declaration of Helsinki guidelines. All patients provided written informed consent before study participation.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All the authors have provided their consent for publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"WY, and DWA are employees and minor stockholders of Eli Lilly and Company. JHF is a former employee of Eli Lilly and Company and was associated with Eli Lilly till the time of manuscript submission. Her current affiliation is Agios.\u00a0XM is an employee of Tech Data Services Company and performs contracted work for Eli Lilly and Company. SB was an employee of Eli Lilly and Company during the conduct of the study. DCB has received research support from Amgen, the Food and Drug Administration and the National Headache Foundation, and is a consultant to\u00a0Allergan, Amgen, Eli Lilly, Lundbeck and Teva.\u00a0She is a section editor for Current Pain and Headache Reports. RBL has received funding from Alder Biopharmaceuticals, Allergan, American Academy of Neurology (other activities), American Headache Society, Amgen, Autonomic Technologies (speaking and teaching), Avanir Pharmaceuticals, Biohaven Pharmaceuticals, Boston Scientific, Dr. Reddy's Laboratories, ElectroCore, Eli Lilly and Company, eNeura Therapeutics, GlaxoSmithKline, Headache (other activities) (personal fees), Informa (speaking and teaching), Merck & Co, Inc., Migraine Research Foundation, National Headache Foundation, Neurology (board membership) (serves on editorial board), National Institute on Aging (other activities), National Institute of Neurological Disorders and Stroke (other activities), Novartis (speaking and teaching) (other activities) (personal fees), Pernix, Teva Pharmaceuticals, Vedanta, and Wolff's Headache 7th and 8th Edition, Oxford University Press, 2009.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"34"}}